Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN

Current HIV Research

Volumn 10, Issue 2, 2012, Pages 171-181

  Bánhegyi, Dénes ^a   Katlama, Christine ^b   da Cunha, Clóvis Arns ^c   Schneider, Stefan ^d   Rachlis, Anita ^e   Workman, Cassy ^f   de Meyer, Sandra ^g   Vandevoorde, Ann ^g   van de Casteele, Tom ^g   Tomaka, Frank ^h  

^a Szent Laszlo Hospital   (Hungary)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Centro Medico Sao Francisco   (Brazil)

^d Living Hope Clinical Foundation   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f AIDS Research Initiative   (Australia)

^g TIBOTEC BVBA   (Belgium)

^h Tibotec Inc   (United States)

Author keywords

Darunavir; Efficacy; HIV; Lopinavir; Safety; TITAN; Treatment experienced; Virology

Indexed keywords

DARUNAVIR; LOPINAVIR; RITONAVIR; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN DISEASE; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOGISTIC MODELS; LOPINAVIR; MALE; MIDDLE AGED; RITONAVIR; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 84860272506     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212799937218     Document Type: Article

References (25)

1. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 14 October 2011. Available at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (access date: 7 November 2011).
2. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 2008; 300: 555-70.
3. Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavirritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78.
4. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007; 46: 24-31.
5. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 49-58.
6. PREZISTA™ (darunavir) Summary of Product Characteristics. December 2010. Available at http://www.emea.europa.eu/humandocs/Humans/EPAR/prezista/prezista.htm (access date: 28 January 2011).
7. Tibotec Inc. PREZISTA™ (darunavir) Prescribing Information. Revised October 2011. Available at http://www.prezista.com/healthcare/full-prescribing-information (access date: 7 November 2011).
8. AIDS Clinical Trials Group. Division of AIDS table for grading the severity of adult and pediatric adverse events. Available at http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf (access date: 28 January 2011).
9. De Meyer S, Vangeneugden T, Van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24: 379-88.
10. Abbott Laboratories. KALETRA® (lopinavir/ritonavir) Prescribing Information. June 2010. Available at http://rxabbott.com/pdf/kaletratabpi.pdf (access date: 28 January 2011).
11. Boehringer Ingelheim. APTIVUS® (tipranavir) June 2009. Available at http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Aptivus/10003515+US+01.pdf (access date: 28 January 2011).
12. European Medicines Agency. Points to consider on switching between superiority and noninferiority. Available at http://www.emea.europa.eu/pdfs/human/ewp/048299en.pdf (access date: 28 January 2011).
13. European Medicines Agency. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: statistical principles for clinical trials (E9). Available at http://www.emea.europa.eu/pdfs/human/ich/036396en.pdf (access date: 28 January 2011).
14. US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval. Available at http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM070968.pdf (access date: 28 January 2011).
15. Pollard RB, Thompson MA, Hicks CB, et al. Phase 3 comparison of lopinavir/ritonavir vs investigator-selected protease inhibitors in single PI-experienced, NNRTI-naive patients: 48-week results of study M98-888 [abstract PL3.2]. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 2004.
16. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19: 685-94.
17. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19: 685-94.
18. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15: 119-25.
19. De Meyer S, Vangeneugden T, Van Baelen B, et al. Resistance profile of darunavir: Combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24: 379-88.
20. Johnson VA, Brun- Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17: 138-45.
21. De Meyer S, Lathouwers E, Dierynck I, et al. Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients [poster O424]. 9th International Congress on HIV and Drug Therapy in HIV Infection, Glasgow, UK, November 2008.
22. National Cholesterol Education Program. National Institute of Health, National Heart, Lung and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), September 2002. Available at http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf (access date: 28 January 2011).
23. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49: 2314-21.
24. Katlama C, Bellos N, Grinsztejn B, et al. POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir 600/100mg bid in treatment-experienced HIV patients [poster P21]. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 2008.
25. Pozniak A, Arastéh K, Molina J-M, et al. POWER 3 analysis: 144- week efficacy and safety results for darunavir/ritonavir 600/100mg bid in treatment-experienced HIV patients [poster P24]. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 2008.